article thumbnail

Magnite Prices $350M Offering

socalTECH

Los Angeles-based Magnite, the sell-side advertising software developer which was previously known as Rubicon Project, says it has priced an offering of $350M in convertible senior notes. The company said the convertible note offering was made to qualified institutional buyers. The notes are due in 2026.

Pricing 113
article thumbnail

Evofem Prices $50M Offering

socalTECH

San Diego-based Evofem Biosciences, which is developing biopharmaceuticals for women's contraception and related areas, says it has priced a $50M, public offering, and also will receive up to an additoinal $50M upon exercise of accompanying short-term warrant.

Pricing 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GoodRx Prices IPO

socalTECH

Santa Monica-based prescription and healthcare marketplace operator GoodRx has priced its IPO, saying late last night that it is offering up 34,615,384 shares of its Class A common stock at $33.00 The company priced well above its initial offering range, which was $24.00 per share, indicating high investor interst in the company.

Pricing 113
article thumbnail

Should you cast your net where the big fish swim?

Berkonomics

But for most, the true sign of success and potential for even more is in the landing of a major account, one that validates the pricing, quality and competitive advantages of a company’s offering. Aim high for that major account.

.Net 156
article thumbnail

Maestro nets $15 million for its interactive commerce, community and engagement tools for livestreams

TechCrunch LA

But what started in the gaming world quickly spun out as the company slashed prices to $500 per month for its services. Initially the LA-based company launched to the gaming community with interactive features that folks could use in-stream to create better engagement with fans.

Tool 315
article thumbnail

Obalon Sets IPO Pricing Range

socalTECH

Carlsbad-based Obalon Therapeutics , which is developing a balloon-based medical device for assisting in weight loss, has set the estimated initial IPO pricing range for its public offering, saying it now expects an initial public offering at between $14.00 if it prices at the high end of its estimated range. and $16.00 READ MORE>>.

Pricing 100
article thumbnail

Cast your net where the big fish swim.

Berkonomics

But for most, the true sign of success and potential for even more is in the landing of a major account, one that validates the pricing, quality and competitive advantages of a company’s offering. For this reason alone, it makes sense for most of us to aim high once we have worked the kinks out of our offering with smaller customers.

.Net 235